EQS-News

    137 Aufrufe 137 0 Kommentare 0 Kommentare

    Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases

    Für Sie zusammengefasst
    • Evotec, Yonsei, Zymedi get $4.5M grant for lung treatments.
    • Funding aims to develop antibodies for asthma, IPF.
    • Collaboration targets novel tRNA synthetase therapies.
    EQS-News - Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases

    EQS-News: Evotec SE / Key word(s): Miscellaneous
    Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases

    22.01.2025 / 07:30 CET/CEST
    The issuer is solely responsible for the content of this announcement.


     
    • Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy
    • Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis
     

    Hamburg, Germany, 22 January 2025:
    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

    “We are excited to work together with Prof. Sunghoon Kim and our colleagues at Zymedi and Yonsei University to cooperatively advance a particularly promising approach to develop novel antibody-based treatments for asthma and IPF,” said Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec. “The synergies between the three parties supported by the KIAT grant showcase how international collaborations can help accelerate the development of novel therapies for diseases with a high unmet medical need: Dr. Kim’s laboratory at Yonsei University has been recognized as a global leader in the field of tRNA synthetases by uncovering their diverse regulatory activities for body homeostasis. Zymedi is an aspiring Korean company translating the pathologic association of tRNA synthetases to new medicine. Evotec will bring to bear its world-class antibody development, engineering and manufacturing technologies together with its integrated preclinical R&D platforms for drug discovery and development of fibrosis and lung diseases. We are grateful to the Korean government and honored to be part of this outstanding consortium”

    Seite 1 von 4



    Diskutieren Sie über die enthaltenen Werte




    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases 22.01.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this …